嵌合抗原受体T细胞治疗：增加有效性和减少毒性的新途径

icartab

Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity.

Abstract

The durable remission of B-cell leukemia and lymphoma following chimeric antigen receptor (CAR) T-cell therapy has brought this new form of adoptive immunotherapy to center stage with the expectation that CAR T-cell therapy may provide similar efficacy in other hematologic and solid cancers. Herein, we review recent advances in the areas of CAR design that improve CAR T-cell proliferation, engraftment, and efficacy, as well as clinical application strategies that are designed to improve clinical efficacy while reducing the risk of toxicity and broaden patient access to this promising form of cancer immunotherapy.

嵌合抗原受体T细胞治疗：增加有效性和减少毒性的新途径

摘要

The durable remission of B-cell leukemia and lymphoma following chimeric antigen receptor (CAR) T-cell therapy has brought this new form of adoptive immunotherapy to center stage with the expectation that CAR T-cell therapy may provide similar efficacy in other hematologic and solid cancers. Herein, we review recent advances in the areas of CAR design that improve CAR T-cell proliferation, engraftment, and efficacy, as well as clinical application strategies that are designed to improve clinical efficacy while reducing the risk of toxicity and broaden patient access to this promising form of cancer immunotherapy.

嵌合抗原受体（CAR）T细胞治疗对B淋巴细胞白血病和淋巴瘤持久缓解作用,这种新形式的以免疫性为主的治疗方式，可能在其他血液和实体肿瘤带来类似的疗效。在此，我们回顾了近年来CAR的设计领域，涉及到提高CAR-T细胞增殖，植入以及疗效。旨在提高临床疗效，减少毒性的风险和扩大病人获得这个很有前途的癌症免疫治疗的临床应用策略。

出自爱康得